Back to top
more

Novartis (NVS)

(Delayed Data from NYSE)

$113.77 USD

113.77
697,183

-0.09 (-0.08%)

Updated Oct 8, 2024 04:00 PM ET

After-Market: $113.76 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

FDA Accepts Sanofi's BLA for Meningitis Vaccine to Review

by Zacks Equity Research

The FDA accepts for review Sanofi's (SNY) BLA for MenQuadfi, a meningococcal vaccine candidate, presently under development to prevent meningococcal meningitis.

Dova Receives Approval for Doptelet in Europe, Stock Up

by Zacks Equity Research

Dova Pharmaceuticals (DOVA) announces approval of its thrombocytopenia drug, Doptelet, in Europe for patients with chronic liver disease.

Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits

by Zacks Equity Research

Activist investor, Elliott Advisors, discloses a 1.1-billion-euro ($1.3 billion) stake in Bayer (BAYRY). It forms a new committee and hires U.S. lawyer Beisner to fight its glyphosate litigations.

Sejuti Banerjea headshot

Is Allergan a Good Deal for AbbVie?

by Sejuti Banerjea

AbbVie is dishing out $63 billion in stock and cash for Allergan, provided it gets regulatory approval.

Conatus' Emricasan Lags Primary Goal in Liver Function Study

by Zacks Equity Research

Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined objectives.

Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval

by Zacks Equity Research

Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.

NVS or NVO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVS vs. NVO: Which Stock Is the Better Value Option?

Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status

by Zacks Equity Research

Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.

Roche's Rozlytrek Gets Approval in Japan for Solid Tumors

by Zacks Equity Research

Roche's (RHHBY) oncology portfolio gets a boost with the approval of Rozlytrek for neurotrophic tyrosine receptor kinase fusion-positive, advanced recurrent solid tumors.

J&J's (JNJ) Tremfya Meets Goal in Psoriatic Arthritis Study

by Zacks Equity Research

J&J's (JNJ) Tremfya meets the primary endpoint in a late stage study that evaluated the efficacy and safety of the drug for treating patients with psoriatic arthritis.

Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz

by Zacks Equity Research

Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.

Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris

by Zacks Equity Research

Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.

Ligand Inks Oncology Drug Discovery Deal With PhoreMost

by Zacks Equity Research

Ligand's (LGND) subsidiary Vernalis enters research agreement with privately-held PhoreMost to design compounds targeting an undisclosed novel oncology target.

Mark Vickery headshot

Top Analyst Reports for Visa, Netflix & Accenture

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Netflix (NFLX) and Accenture (ACN).

Roche's Rituxan Gets Priority Review for Blood Disorder

by Zacks Equity Research

Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.

Novartis Reports Data on Cosentyx for Psoriatic Arthritis

by Zacks Equity Research

Novartis (NVS) announces new data on psoriatic arthritis drug, Cosentyx.

Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug

by Zacks Equity Research

Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.

Roche Receives FTC Request for Further Data on Spark Buyout

by Zacks Equity Research

Roche (RHHBY) gets additional information request from FTC for the pending Spark acquisition.

Celgene's Filing for Ozanimod Accepted for Review in US/EU

by Zacks Equity Research

The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.

Novartis Appoints New Pharma Unit Head, Gives Other Updates

by Zacks Equity Research

Novartis (NVS) appoints Marie-France Tschudin as head of the pharma unit. The company also provides a few pipeline updates.

Alnylam Completes Rolling NDA Submission to FDA for Givosiran

by Zacks Equity Research

Alnylam (ALNY) completes the rolling NDA submission to the FDA for givosiran, which is being evaluated for the treatment of acute hepatic porphyria.

Incyte Begins Phase III Study for Treatment of Duct Cancer

by Zacks Equity Research

Incyte (INCY) begins first phase III study of pemigatinib as a first-line therapy for patients with metastatic or surgically unresectable cholangiocarcinoma.

Kinjel Shah headshot

Was ASCO Quieter for Big Drug/Biotech Stocks This Year?

by Kinjel Shah

The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago sees cancer data presentations from several drug/biotech companies about the latest developments in treating cancer.

Aduro Stock Crashes After ASCO Updates on Cancer Candidate

by Zacks Equity Research

Aduro (ADRO) presents updated data from an ongoing phase Ib study evaluating its STING agonist, ADU-S100 in combination with Novartis' checkpoint inhibitor.

Novartis (NVS) Announces Various Data Presentations at ASCO

by Zacks Equity Research

Novartis (NVS) announces a number of data presentations at the ASCO 2019 annual meeting.